Cart
sales@molnova.com
ER-34122
CAS No. 179325-62-3
ER-34122( —— )
Catalog No. M36331 CAS No. 179325-62-3
ER-34122, a novel orally available dual 5-lipoxygenase/cyclooxygenase inhibitor, exhibits potent anti-inflammatory activity in an arachidonic acid-induced ear inflammation model.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 276 | In Stock |
|
| 10MG | 394 | In Stock |
|
| 25MG | 616 | In Stock |
|
| 50MG | 830 | In Stock |
|
| 100MG | 1097 | In Stock |
|
| 200MG | 1479 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameER-34122
-
NoteResearch use only, not for human use.
-
Brief DescriptionER-34122, a novel orally available dual 5-lipoxygenase/cyclooxygenase inhibitor, exhibits potent anti-inflammatory activity in an arachidonic acid-induced ear inflammation model.
-
DescriptionER-34122, a novel orally available dual 5-lipoxygenase/cyclooxygenase inhibitor, exhibits potent anti-inflammatory activity in an arachidonic acid-induced ear inflammation model.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayImmunology/Inflammation
-
TargetLipoxygenase
-
RecptorLipoxygenase
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number179325-62-3
-
Formula Weight507.96
-
Molecular FormulaC27H26ClN3O5
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESO=C(N)C1=CC(=CC=C1Cl)C(OC)(OC)C2=NN(C3=CC=C(OC)C=C3)C(=C2)C=4C=CC(OC)=CC4
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
molnova catalog
related products
-
CJ-13,610 hydrochlor...
CJ-13,610 hydrochloride is an orally active nonredox-type inhibitor of 5-LOX and can be used in studies about the prevention of untoward pathophysiological effects of LTs.
-
PF-04191834
PF-04191834 (PF-4191834) is a potent, non‐iron chelating, non‐redox, selective and competitive inhibitor of 5-lipoxygenase (5‐LO) with Ki of 10 nM.
-
Masoprocol
Masoprocol (meso-Nordihydroguaiaretic acid) is a potent, orally active lipoxygenase inhibitor that exhibits antihyperglycemic activity, making it potentially valuable for type II diabetes research. In vivo, Masoprocol reduces glucose and hepatic triglyceride concentrations .
